MARKET WIREYahoo • 1d ago
What Just Happened To Alnylam Stock?For questions about this article or underlying research, email help@trefis.com.
Why IONS Stock slipped -1.14% Today — RQD Quant Desk Flash
$44.39 -1.14% NASDAQ • Public Delayed / 60s Snapshot
Ionis Pharmaceuticals Inc. (IONS) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh money.
ROARABLE D+ • SELL / AVOID
Cap $7.38B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERSELL / AVOID • D+
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw D · Rk B
Each axis scored 0–20
12M PRICE TARGET CONE+0% Base Target
WHALE OPTIONS TUG-OF-WAR:51% Call Buyers ($2.3M)
49% PutsMax Pain: $44.00
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why IONS Stock slipped -1.14% Today — RQD Quant Desk Flash
Ionis Pharmaceuticals Inc. (IONS) slipped -1.14% to $44.39 as options desks priced 51% call premium vs. 49% put protection around the $44 max-pain magnet. Stretched risk/reward at current multiples (-21% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 5% of its 52-week range ($42.08 – $86.74) with RSI-14 at 43.1 (NEUTRAL RANGE).
- ▸Whale Options Positioning: $2.3M in bullish call flow vs. $2.2M in put flow (Put/Call 0.97x, implied earnings swing ±7.2%).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 98.3% gross margin and $0 annual free cash flow.
Live IONS Headlines & Catalysts
CATALYSTYahoo • 2d ago
Alnylam Sinks 19% as It Expands Nucresiran Heart Trial Again, Citing “A High Level of Conviction”Key TakeawaysAlnylam shares fell 19% after it expanded its nucresiran heart trial for the second time this year, despite 52% growth in product revenue. Sizing the trial for fewer cardiovascular events than planned raises
CATALYSTYahoo • 2d ago
ARS Pharmaceuticals, Inc. (SPRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseARS Pharmaceuticals, Inc. (SPRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CATALYSTYahoo • 3d ago
Earnings Preview: Ionis Pharmaceuticals (IONS) Q3 Earnings Expected to DeclineIonis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CATALYSTYahoo • 4d ago
NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues MissNovartis beats Q3 earnings estimates and raises its 2026 operating income outlook as Kisqali, Kesimpta and Scemblix offset generic competition.
MARKET WIRESeekingAlpha • 5d ago
Artisan Mid Cap Fund Q3 2026 Portfolio UpdateDuring the quarter, we initiated new positions in Manhattan Associates, Okta and Clean Harbors. Read more here.
CATALYSTSeekingAlpha • 6d ago
Ionis Pharmaceuticals: Compelling Long-Term Commercial UpsideIonis Pharmaceuticals, Inc. is a long-term buy as launches, royalties, & pipeline growth boost revenue prospects despite cash burn. Click for an IONS stock update.
MARKET WIREYahoo • 8d ago
Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)CARLSBAD, Calif., October 23, 2026--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Roche announced today late-breaking oral presentation data from the ongoing Phase 3 IMAgINATION study in adults with primary IgA neph
MARKET WIREYahoo • 9d ago
Ionis ranked #1 on Science’s Top Employers listCARLSBAD, Calif., October 22, 2026--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the company was named the top employer to work for by Science in its annual Top Employers survey of the biotech and phar
MARKET WIREYahoo • 9d ago
Ionis Pharmaceuticals Secures FDA Orphan Drug Designation For Rare Epilepsy TreatmentThe treatment targets the SCN1A gene, which helps the brain produce a protein that controls electrical activity and prevents seizures
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Forensic Quant Desk
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring IONS)
- ✓Live walkthrough of IONS's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
IONS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -41.79%📐 HORIZONTAL RANGE
2026-10-30O $44.69H $45.12L $43.27C $43.52VOL 1.52M
RES: $103.7SUP: $38.71SMA50: $49.02SMA200: $66.79
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
IONS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
15.7%/yr Implied 5Y Growth
vs. +33.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on IONS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for IONS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IONS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
IONS Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is IONS stock moving today?
Why IONS Stock slipped -1.14% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-21% return on capital) under elevated 10-year interest-rate pressure.